Important Notice for Investors: Rosen Law Firm Reminds Purchasers of GSK plc ADRs of Deadline in Securities Class Action Lawsuit
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (ADRs) of GSK plc (NYSE:GSK) between February 5, 2020, and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025, lead plaintiff deadline in a securities class action lawsuit. The lawsuit was filed in the United States District Court for the Southern District of New York.
What Happened to GSK plc?
According to the lawsuit, defendants during the Class Period made false and/or misleading statements and/or failed to disclose that:
- GSK was experiencing manufacturing issues with its shingles vaccine, Shingrix, which would impact its production and sales;
- GSK was experiencing manufacturing delays with its HIV drug, Cabenuva;
- GSK was experiencing manufacturing issues with its respiratory syncytial virus (RSV) vaccine, Synagis;
- GSK was experiencing manufacturing issues with its monkeypox vaccine, Imvanex;
As a result of these false and/or misleading statements and/or omissions, the price of GSK’s ADRs was artificially inflated during the Class Period.
Who is Eligible?
If you purchased GSK ADRs during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is April 7, 2025.
What Does This Mean for Me?
If you purchased GSK ADRs during the Class Period, you may have valuable legal rights. You may be able to recover your losses by joining the class action lawsuit. The lead plaintiff deadline is April 7, 2025. To join the class action, you must file a motion with the court no later than this date.
What Does This Mean for the World?
The securities class action lawsuit against GSK plc is an important step in holding the company accountable for any misrepresentations made to investors during the Class Period. The lawsuit seeks to recover damages for investors who suffered losses as a result of these misrepresentations. It is also an opportunity for investors to hold corporations accountable for their actions and to ensure transparency and accuracy in financial reporting.
Conclusion
If you purchased GSK ADRs during the Class Period and believe that you have suffered losses as a result of the company’s false and/or misleading statements and/or omissions, you may be entitled to compensation. The lead plaintiff deadline is April 7, 2025. To join the class action lawsuit, you must file a motion with the court no later than this date. For more information, please contact Rosen Law Firm at 212-686-1060 or via email at [email protected].
About Rosen Law Firm, P.A:
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and other complex litigation. The firm was Ranked No. 1 in the number of securities class action settlements in 2019 and 2020 according to ISS Securities Class Action Services. The firm has recovered hundreds of millions of dollars for investors.
Contact Information:
Rosen Law Firm, P.A
30 Rockefeller Plaza, 22nd Floor
New York, NY 10112
Phone: 212-686-1060
Fax: 212-202-3827
Email: [email protected]
Website: www.rosenlegal.com
Gleason Willock, Esq. or Adam Elman, Esq.
Attorney Advertising. Prior results do not guarantee a similar outcome.
